FindMyKOL
Clinical trialNCT05384015Active, not recruitingPhase 2Interventional

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

SponsorFundación GECPEnrollment46Small Cell Lung Cancer Extensive Stage
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multicenter, open-label, non-randomized, single arm, 2 parts, phase II clinical trial evaluating the efficacy and safety of pembrolizumab and lenvatinib plus standard of care chemotherapy (with carboplatin and etoposide ) in subjects with histologically confirmed extensive-stage small-cell lung cancer who have not previously received systemic therapy for this malignancy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Spain
  • Hospital General Universitario de Alicante

    Alicante, Alicante, Spain

  • Ico Badalona, Hospital Germans Trias I Pujol

    Badalona, Barcelona, Spain

  • Hospital Clínic de Barcelona

    Barcelona, Barcelona, Spain

  • Hospital Parc Taulí

    Barcelona, Barcelona, Spain

  • Hospital Universitari Vall D' Hebron

    Barcelona, Barcelona, Spain

  • Hospital de la Santa Creu I Sant Pau

    Barcelona, Barcelona, Spain

  • Hospital de Basurto

    Bilbao, Bilbao, Spain

  • Ico Girona, Hospital Josep Trueta

    Girona, Girona, Spain

  • Hospitalario Universitario A Coruña

    A Coruña, La Coruña, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, Lugo, Spain

  • Hospital 12 de Octubre

    Madrid, Madrid, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Madrid, Spain

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Madrid, Spain

  • Hospital Universitario Regional de Málaga

    Málaga, Málaga, Spain

  • Hospital Son Espases

    Palma de Mallorca, Palma de Mallorca, Spain

  • Complejo Hospitalario de Navarra

    Pamplona, Pamplona, Spain

  • Hospital Clínico de Valencia

    Valencia, Valencia, Spain

  • Hospital General Universitario de Valencia

    Valencia, Valencia, Spain

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Etoposide →Lenvatinib →Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Nov 2022
Primary completion
30 Jul 2027
Completion
30 Dec 2027
Last update posted
30 Apr 2026
Registered enrollment
46
Registry id
NCT05384015

Cross-registrations

EU-CTR / CTIS (EudraCT)2020-005230-15
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.